Pioneering botulism antitoxin from Cangene gets FDA nod

03/25/2013 | Medscape (free registration) · Reuters

The FDA approved Cangene's Botulism Antitoxin Heptavalent to treat patients with suspected or documented exposure to all known botulinum neurotoxin serotypes. The horse plasma-based antitoxin is the only botulism treatment available for adults and for infants whose illness was caused by toxins other than types A and B. Because the drug holds an orphan-drug designation, it will get seven years of market exclusivity.

View Full Article in:

Medscape (free registration) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Group Health Cooperative
Group Health Cooperative
Seattle, WA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)